Short answer
Bioventus Inc. (BVS) filed an 8-K current report with the SEC on May 21, 2026 reporting Item 7.01 (Regulation FD Disclosure). FDA reclassified Exogen and similar stimulators from Class III to Class II on April 16, 2026.
Bioventus Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA reclassified Exogen and similar stimulators from Class III to Class II on April 16, 2026
- CMS billing and Medicare fee schedule changes take effect May 18, 2026 for HCPCS E0747, E0748, and E0760
- Bioventus expects no material fiscal 2026 impact and reiterated existing guidance
- Potential future CMS reimbursement changes remain the primary longer-term risk to Exogen revenue
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bioventus Inc. 8-K filings
Get the next BVS 8-K as it lands
Follow BVS for push alerts, or ask the research agent what this filing means.